Literature DB >> 21683507

Model system using controlled receptor expression for evaluating targeted ultrasound contrast agents.

Reshu Saini1, Jason M Warram, Anna G Sorace, Heidi Umphrey, Kurt R Zinn, Kenneth Hoyt.   

Abstract

This report details a model system for evaluating targeted ultrasound (US) contrast agents using adenoviral (Ad) vectors to regulate target receptor expression. Receptor density in vitro was modulated in breast cancer cells by varying the multiplicity of infection (MOI) from 0 to 100. Target receptors were induced using a green fluorescent protein (GFP) reporter Ad vector for gene transfer and expression of the hemagglutinin (HA) tag. These reporter genes were under the control of the ubiquitous cytomegalovirus (CMV) promoter. Subsequently, receptor expression and anti-HA antibody (Ab) binding was examined with flow cytometry. Targeted US contrast agents, or microbubbles (MB), were created by conjugating either biotinylated anti-HA or isotype control Ab to the surface of biotin coated MBs via a streptavidin bridge. Targeted MBs were incubated with Ad infected 2LMP cells to evaluate in vitro MB binding. Experimental results found GFP expression to be directly correlated with Ad MOI (r² = 0.96). Increasing the Ad MOI produced a corresponding increase in binding and accumulation of anti-HA Ab on the cell surface (p < 0.01). However, no difference was found between Cy5-labeled anti-HA Ab exposed cell groups at an MOI of 0 (p > 0.29). Additionally, no difference was found between the isotype control Ab group (p > 0.44) indicating minimal nonspecific binding. No difference was found between cell groups incubated with isotype-targeted MBs (p > 0.42) regardless of receptor density. However, cells exposed to HA-targeted MBs showed increased levels of cell binding proportional to induced receptor expression levels (p < 0.02).
Copyright © 2011 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21683507      PMCID: PMC3129442          DOI: 10.1016/j.ultrasmedbio.2011.05.010

Source DB:  PubMed          Journal:  Ultrasound Med Biol        ISSN: 0301-5629            Impact factor:   2.998


  25 in total

1.  Modulating targeted adhesion of an ultrasound contrast agent to dysfunctional endothelium.

Authors:  Gregory E R Weller; Flordeliza S Villanueva; Alexander L Klibanov; William R Wagner
Journal:  Ann Biomed Eng       Date:  2002-09       Impact factor: 3.934

Review 2.  Microbubbles in medical imaging: current applications and future directions.

Authors:  Jonathan R Lindner
Journal:  Nat Rev Drug Discov       Date:  2004-06       Impact factor: 84.694

Review 3.  Development and use of biomarkers in oncology drug development.

Authors:  Eugenia Floyd; Teresa M McShane
Journal:  Toxicol Pathol       Date:  2004 Mar-Apr       Impact factor: 1.902

Review 4.  Virus yoga: the role of flexibility in virus host cell recognition.

Authors:  Eugene Wu; Glen R Nemerow
Journal:  Trends Microbiol       Date:  2004-04       Impact factor: 17.079

5.  A triple-targeted ultrasound contrast agent provides improved localization to tumor vasculature.

Authors:  Jason M Warram; Anna G Sorace; Reshu Saini; Heidi R Umphrey; Kurt R Zinn; Kenneth Hoyt
Journal:  J Ultrasound Med       Date:  2011-07       Impact factor: 2.153

6.  Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice.

Authors:  Kurt R Zinn; Tandra R Chaudhuri; Victor N Krasnykh; Donald J Buchsbaum; Natalya Belousova; William E Grizzle; David T Curiel; Buck E Rogers
Journal:  Radiology       Date:  2002-05       Impact factor: 11.105

7.  Ultrasound assessment of inflammation and renal tissue injury with microbubbles targeted to P-selectin.

Authors:  J R Lindner; J Song; J Christiansen; A L Klibanov; F Xu; K Ley
Journal:  Circulation       Date:  2001-10-23       Impact factor: 29.690

8.  Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to alpha(v)beta3.

Authors:  Dilantha B Ellegala; Howard Leong-Poi; Joan E Carpenter; Alexander L Klibanov; Sanjiv Kaul; Mark E Shaffrey; Jiri Sklenar; Jonathan R Lindner
Journal:  Circulation       Date:  2003-06-30       Impact factor: 29.690

9.  Noninvasive assessment of angiogenesis by ultrasound and microbubbles targeted to alpha(v)-integrins.

Authors:  Howard Leong-Poi; Jonathan Christiansen; Alexander L Klibanov; Sanjiv Kaul; Jonathan R Lindner
Journal:  Circulation       Date:  2003-01-28       Impact factor: 29.690

10.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

View more
  4 in total

1.  Molecular ultrasound imaging using a targeted contrast agent for assessing early tumor response to antiangiogenic therapy.

Authors:  Anna G Sorace; Reshu Saini; Marshall Mahoney; Kenneth Hoyt
Journal:  J Ultrasound Med       Date:  2012-10       Impact factor: 2.153

2.  An animal model allowing controlled receptor expression for molecular ultrasound imaging.

Authors:  Reshu Saini; Anna G Sorace; Jason M Warram; Marshall J Mahoney; Kurt R Zinn; Kenneth Hoyt
Journal:  Ultrasound Med Biol       Date:  2012-11-02       Impact factor: 2.998

Review 3.  Antibody-based imaging strategies for cancer.

Authors:  Jason M Warram; Esther de Boer; Anna G Sorace; Thomas K Chung; Hyunki Kim; Rick G Pleijhuis; Gooitzen M van Dam; Eben L Rosenthal
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

4.  Recent developments in dynamic contrast-enhanced ultrasound imaging of tumor angiogenesis.

Authors:  Reshu Saini; Kenneth Hoyt
Journal:  Imaging Med       Date:  2014-02-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.